Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Purpose:

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.


Criteria:

Inclusion Criteria: - Solid tumors or lymphoid malignancies refractory to standard therapy - measurable disease - recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy - no chemotherapy within 4 weeks of entering study - Age > 18 years - Karnofsy >= 60% - Life expectancy > 3 months - normal or adequate organ and marrow function Exclusion Criteria: - receiving other investigational agents - brain metastases - uncontrolled medical illness - HIV+ receiving combination antiretroviral therapy - significant GI disease


NCT ID:

NCT00647764


Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20892
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.